Female gender as a susceptibility factor for drug-induced liver injury

Human and Experimental Toxicology

Volumn 33, Issue 9, 2014, Pages 928-939

  Amacher, David E ^a  

^a Toxadvisor Toxicology Consulting   (United States)

Author keywords

adverse drug response; Drug induced liver injury; female gender

Indexed keywords

ABACAVIR; ALCOHOL DEHYDROGENASE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIRHEUMATIC AGENT; CARBAMAZEPINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DIETHYLSTILBESTROL; DISULFIRAM; DRUG; DRUG BINDING PROTEIN; DRUG METABOLITE; GLUTATHIONE TRANSFERASE A1; HEPARIN; HLA ANTIGEN; IMMUNOMODULATING AGENT; ISONIAZID; ORAL CONTRACEPTIVE AGENT; TESTOSTERONE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ACUTE LIVER FAILURE; ADAPTIVE IMMUNITY; ADIPOSE TISSUE; ARTICLE; AUTOIMMUNE HEPATITIS; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG INTOXICATION; DRUG METABOLISM; DRUG SURVEILLANCE PROGRAM; FEMALE; FEMININITY; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; INTERNATIONAL CLASSIFICATION OF DISEASES; INTESTINE BLOOD FLOW; INTESTINE TRANSIT TIME; KIDNEY BLOOD FLOW; KUPFFER CELL; LIVER CELL; LIVER TOXICITY; MENOPAUSE; MENSTRUATION; NONHUMAN; POSTMARKETING SURVEILLANCE; PREGNANCY; PRIORITY JOURNAL; SEX DIFFERENCE; STOMACH ACID SECRETION; STOMACH EMPTYING; TOXIC HEPATITIS; ADVERSE DRUG REACTION; DRUG EFFECTS; LIVER; MALE; RISK FACTOR;

DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; LIVER; MALE; RISK FACTORS; SEX FACTORS;

EID: 84904868563     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327113512860     Document Type: Article

References (102)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998 ; 279 (15). 1200-1205
2. Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008 ; 42 (7). 1017-1025
3. Zopf Y, Rabe C, Neubert A. Women encounter ADRs more often than do men. Eur J Clin Pharmacol. 2008 ; 64 (10). 999-1004
4. Rademaker M. Do women have more adverse drug reactions?. Am J Clin Dermatol. 2001 ; 2 (6). 349-351
5. HeinrichJ.www.gao.gov/products/GAO-01-286RDrug Safety: Most Drugs Withdrawn in Recent Years Had Greater Health Risks for Women. GAO-01-286R, Jan 19, 2001, Washington: US General Accounting Office.
6. Miller MA. Gender-based differences in the toxicity of pharmaceuticals: the food and drug administration's perspective. Int J Toxicol. 2001 ; 20: 149-152
7. Fishman JR, Wick JG, Koenig BA. The use of "sex" and "gender" to define and characterize meaningful differences between men and women. Agenda for Research on Women's Health for the 21st Century. 1999 ; Vol. 1: 15-19
8. Fletcher CV, Acosta EP, Strykowski JM. Gender differences in human pharmacokinetics and pharmacodynamics. J Adolesc Health. 1994 ; 15 (8). 619-629
9. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs. 1995 ; 50 (2). 222-239
10. Whitley H, Lindsey W. Sex-based differences in drug activity. Am Fam Physician. 2009 ; 80 (11). 1254-1258
11. Ghazeeri G, Abdullah L, Abbas O. Immunological differences in women compared with men: overview and contributing factors. Am J Reprod Immunol. 2011 ; 66 (3). 163-169
12. Glaeske G, Gerdau-Heitmann C, Höfel F, Schicktanz C. "Gender-specific drug prescription in Germany" results from prescriptions analyses. Handb Exp Pharmacol. 2012 ; (214). 149-167
13. Zopf Y, Rabe C, Neubert A, et al. Gender-based differences in drug prescription: relation to adverse drug reactions. Pharmacology. 2009 ; 84 (6). 333-339
14. WHO. Pharmacovigilance: Ensuring the safe use of medicines - WHO policy perspectives on medicines, no. 009, 2004. Available at:http://apps.who.int/ medicinedocs/en/d/Js6164e/(2004, accessed 10 July 2013).Geneva, Switzerland: WHO.
15. Khosla S, Somberg JC. Gender differences in drug therapy. Am J Ther. 1996 ; 3 (10). 735-739
16. Rasmussen SA. Human teratogens update 2011: can we ensure safety during pregnancy?. Birth Defects Res A Clin Mol Teratol. 2012 ; 94 (3). 123-128
17. US Food. Guideline for the study and evaluation of gender differences in the clinical evaluation of drugs. Fed Reg. 1993 ; 58: 39406-30416
18. Pinnow E, Sharma P, Parekh A, Gevorkian N, Uhl K. Increasing participation of women in early phase clinical trials approved by the FDA. Womens Health Issues. 2009 ; 19 (2). 89-93
19. NIH Guidelines on the inclusion of women and minorities as subjects in clinical research (1994) 59 Fed. Reg. 1450814513; as amended October, 2001.
20. World Health Organization. Safety of Medicines. A guide to detecting and reporting adverse drug reactions. Why health professionals need to take action. Available at:whqlibdoc.who.int/hq/2002/WHO-EDM-QSM-2002.2.pdf. (2002, accessed 10 July 2013). Geneva, Switzerland: WHO, 2002.
21. Waxman DJ, Holloway MG. Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol. 2009 ; 76 (2). 215-228
22. Yang L, Li Y, Hong H, et al. Sex differences in the expression of drug-metabolizing and transporter genes in human liver. J Drug Metab Toxicol. 2012 ; 3 (3). 1-9
23. Anderson GD. Gender differences in pharmacological response. Int Rev Neurobiol. 2008 ; 83: 1-10
24. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003 ; 42 (2). 107-121
25. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009 ; 41 (2). 89-295
26. Yang L, Price ET, Chang CW, et al. Gene expression variability in human hepatic drug metabolizing enzymes and transporters. PLoS One. 2013 ; 8 (4). e60368
27. Zhou SF, Yang LP, Zhou ZW, et al. Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J. 2009 ; 11 (3). 481-494
28. Parkinson A, Mudra DR, Johnson C, et al. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol. 2004 ; 199 (3). 193-209
29. Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics?. Clin Pharmacokinet. 2002 ; 41 (5). 329-342
30. Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 2008 ; 9 (4). 310-322
31. Anderson GD. Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J Womens Health (Larchmt). 2005 ; 14 (1). 19-29
32. Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther. 1999 ; 24 (5). 339-346
33. Isoherranen N, Thummel KE. Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes?. Drug Metab Dispos. 2013 ; 41 (2). 256-262
34. Kennedy M. Hormonal regulation of hepatic drug-metabolizing enzyme activity during adolescence. Clin Pharmacol Ther. 2008 ; 84 (6). 662-673
35. Flynn TJ, Ferguson MS. An in vitro system for studying potential biological mechanisms of human sex differences in susceptibility to acute liver injury. Toxicol Lett. 2010 ; 198 (2). 232-236
36. van der Hooft CS, Sturkenboom MC, van Grootheest K, Kingma HJ, Stricker BH. Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands. Drug Saf. 2006 ; 29 (2). 161-168
37. Zopf Y, Rabe C, Neubert A, et al. Risk factors associated with adverse drug reactions following hospital admission: a prospective analysis of 907 patients in two German university hospitals. Drug Saf. 2008 ; 31 (9). 789-798
38. Fattinger K, Roos M, Vergères P, et al. Epidemiology of drug exposure and adverse drug reactions in two swiss departments of internal medicine. Br J Clin Pharmacol. 2000 ; 49 (2). 158-167
39. Martin RM, Biswas PN, Freemantle SN, et al. Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies. Br J Clin Pharmacol. 1998 ; 46 (5). 505-511
40. Rodenburg EM, Stricker BH, Visser LE. Sex-related differences in hospital admissions attributed to adverse drug reactions in the Netherlands. Br J Clin Pharmacol. 2011 ; 71 (1). 95-104
41. Domecq C, Naranjo CA, Ruiz I, Busto U. Sex-related variations in the frequency and characteristics of adverse drug reactions. Int J Clin Pharmacol Ther Toxicol. 1980 ; 18 (8). 362-366
42. Zopf Y, Rabe C, Neubert A, et al. Women encounter ADRs more often than do men. Eur J Clin Pharmacol. 2008 ; 64 (10). 999-1004
43. Rodenburg EM, Stricker BH, Visser LE. Sex differences in cardiovascular drug-induced adverse reactions causing hospital admissions. Br J Clin Pharmacol. 2012 ; 74 (6). 1045-1052
44. Montastruc JL, Lapeyre-Mestre M, Bagheri H, Fooladi A. Gender differences in adverse drug reactions: analysis of spontaneous reports to a regional pharmacovigilance centre in France. Fundam Clin Pharmacol. 2002 ; 16 (5). 343-346
45. World Health Organization. International Classification of Diseases (ICD), Zurich, Switzerland, WHO. 2010 Edition. Available at: http://www.who.int/classifications/icd/en/. (accessed 10 July 2013).
46. Miguel A, Marques B, Freitas A, et al. Detection of adverse drug reactions using hospital databases-a nationwide study in Portugal. Pharmacoepidemiol Drug Saf. 2013 ; 22 (8). 907-913
47. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004 ; 329 (7456). 15-19
48. Andrade RJ, Agúndez JA, Lucena MI, et al. Pharmacogenomics in drug induced liver injury. Curr Drug Metab. 2009 ; 10 (9). 956-970
49. Li J, Uetrecht JP. The danger hypothesis applied to idiosyncratic drug reactions. Handb Exp Pharmacol. 2010 ; (196). 493-509
50. Pichler WJ, Beeler A, Keller M, Lerch M, Posadas S, Schmid D, et al. Pharmacological interaction of drugs with immune receptors: the p-i concept. Allergol Int. 2006 ; 55 (1). 17-25
51. Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem. 2009 ; 16 (23). 3041-3053
52. Ghabril M, Chalasani N, Björnsson E. Drug-induced liver injury: a clinical update. Curr Opin Gastroenterol. 2010 ; 26 (3). 222-226
53. Daly AK. Pharmacogenomics of adverse drug reactions. Genome Med. 2013 ; 5 (1). 5
54. Pirmohamed M. Genetics and the potential for predictive tests in adverse drug reactions. Chem Immunol Allergy. 2012 ; 97: 18-31
55. Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis. 2002 ; 6 (3). 755-774
56. Friis H, Andreasen PB. Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish committee on adverse drug reactions between 1978 and 1987. J Intern Med. 1992 ; 232 (2). 133-138
57. Idilman R, et al. The characteristics and clinical outcome of drug-induced liver injury: a single-center experience. J Clin Gastroent erol. 2010 ; 44 (6). e128 - e132
58. Suzuki A, Andrade RJ, Bjornsson E, et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf. 2010 ; 33 (6). 503-522
59. Suk KT, Kim DJ. Drug-induced liver injury: present and future. Clin Mol Hepatol. 2012 ; 18 (3). 249-257
60. Lucena MI, et al. Assessment of drug-induced liver injury in clinical practice. Fundam Clin Pharmacol. 2008 ; 22 (2). 141-158
61. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002 ; 36 (2). 451-455
62. Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009 ; 32 (1). 55-68
63. Fontana RJ, Seeff LB, Andrade RJ, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology. 2010 ; 52 (2). 730-742
64. Meier Y, Cavallaro M, Roos M, et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol. 2005 ; 61 (2). 135-143
65. Eagon PK. Alcoholic liver injury: influence of gender and hormones. Eur J Clin Pharmacol. 2010 ; 16 (11). 1377-1384
66. Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009 ; 48 (3). 143-157
67. Thurman RG. Sex-related liver injury due to alcohol involves activation of Kupffer cells by endotoxin. Can J Gastroenterol. 2000 ; 14 (Suppl D). 129D - 135D
68. Kwo PY, et al. Gender differences in alcohol metabolism: relationship to liver volume and effect of adjusting for body mass. Gastroenterology. 1998 ; 115 (6). 1552-1557
69. Kono H, Wheeler MD, Rusyn I, et al. Gender differences in early alcohol-induced liver injury: role of CD14, NF-kappaB, and TNF-alpha. Am J Physiol Gastrointest Liver Physiol. 2000 ; 278 (4). G652 - G661
70. Müller C. Liver, alcohol and gender. Wien Med Wochenschr. 2006 ; 156 (19-20). 523-526
71. Attia SM.. Deleterious effects of reactive metabolites. Oxid Med Cell Longev. 2010 ; 3 (4). 238-253
72. Dahlin DC, Miwa GT, Lu AY, Nelson SD. N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen. Proc Natl Acad Sci USA. 1984 ; 81 (5). 1327-1331
73. David S, Hamilton JP. Drug-induced Liver Injury. US Gastroenterol Hepatol Rev. 2010 ; 6: 73-80
74. Gonzalez FJ., The 2006 Bernard B. Brodie award lecture. Cyp2e1. Drug Metab Dispos. 2007 ; 35 (1). 1-8
75. Miners JO, Attwood J, Birkett DJ. Influence of sex and oral contraceptive steroids on paracetamol metabolism. Br J Clin Pharmacol. 1983 ; 16 (5). 503-509
76. Navarro SL, et al. UGT1A6 and UGT2B15 polymorphisms and acetaminophen conjugation in response to a randomized, controlled diet of select fruits and vegetables. Drug Metab Dispos. 2011 ; 39 (9). 1650-1657
77. Court MH. Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab Rev. 2010 ; 42 (1). 209-224
78. James LP, et al. Pharmacokinetics of acetaminophen-protein adducts in adults with acetaminophen overdose and acute liver failure. Drug Metab Dispos. 2009 ; 37 (8). 1779-1784
79. Dienstag JL Harrison's Principles of Internal Medicine. 17 th ed. New York, NY: McGraw Hill, 2008, p. 1951. Fauci AS Braunwald E Kasper DL Hauser SL Longo DL Jameson JL Loscalzo J, ed. New York, NY: McGraw Hill ; 2008: 1951.
80. Ju C, Reilly T. Role of immune reactions in drug-induced liver injury (DILI). Drug Metab Rev. 2012 ; 44 (1). 107-115
81. McGill MR, et al. The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation. J Clin Invest. 2012 ; 122 (4). 1574-1583
82. Kjartansdottir I, Bergmann OM, Arnadottir RS, Björnsson ES. Paracetamol intoxications: a retrospective population-based study in Iceland. Scand J Gastroenterol. 2012 ; 47 (11). 1344-1352
83. Craig DG, Bates CM, Davidson JS, Martin KG, Hayes PC, Simpson KJ. Overdose pattern and outcome in paracetamol-induced acute severe hepatotoxicity. Br J Clin Pharmacol. 2011 ; 71 (2). 273-282
84. Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an overview. Expert Opin Drug Saf. 2007 ; 6 (6). 673-684
85. Uetrecht J, Naisbitt DJ. Idiosyncratic adverse drug reactions: current concepts. Pharmacol Rev. 2013 ; 65 (2). 779-808
86. Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology. 2010 ; 52 (6). 2065-2076
87. Ostapowicz G, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002 ; 137 (12). 947-954
88. Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005 ; 42 (6). 1364-1372
89. Russo MW, Galanko JA, Shrestha R, et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 2004 ; 10 (8). 1018-1023
90. Smith ID, Simpson KJ, Garden OJ, Wigmore SJ. Non-paracetamol drug-induced fulminant hepatic failure among adults in Scotland. Eur J Gastroenterol Hepatol. 2005 ; 17 (2). 161-167
91. Zimmerman HJ Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2 nd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 1999, pp. 130-136. Philadelphia, PA: Lippincott Williams & Wilkins ; 1999: 130-136.
92. Andrade RJ, Kaplowitz N, et al. Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology. 2006 ; 44 (6). 1581-1588
93. De Valle MB, Av Klinteberg V, Alem N, et al. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther. 2006 ; 24 (8). 1187-1195
94. Lucena MI, Andrade RJ, Kaplowitz N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology. 2009 ; 49 (6). 2001-2009
95. Andrade RJ, Lucena MI, Fernández MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005 ; 129 (2). 512-521
96. Lucena MI, Molokhia M, Shen Y, et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology. 2011 ; 141 (1). 338-347
97. Vergani D, Longhi MS, Bogdanos DP, et al. Autoimmune hepatitis. Semin Immunopathol. 2009 ; 31 (3). 421-435
98. Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011 ; 56 (4). 958-976
99. Björnsson E, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010 ; 51 (6). 2040-2048
100. Gaillard RC, Spinedi E. Sex- and stress-steroids interactions and the immune system: evidence for a neuroendocrine-immunological sexual dimorphism. Domest Anim Endocrinol. 1998 ; 15 (5). 345-352
101. Lindquist M.. VigiBase, The WHO global ICSR database system: basic facts. Drug Inf J. 2008 ; 42 (05). 409-419
102. Petronijevic M, Ilic K. Associations of gender and age with the reporting of drug-induced hepatic failure: data from the VigiBase™. J Clin Pharmacol. 2013 ; 53 (4). 435-443